Fontán G, García M C, Pascual-Salcedo D, López Trascasa M, Alvarez Doforno R, Ferreira A
Unidad de Inmunología, Hospital La Paz, Madrid, España.
An Esp Pediatr. 1992 Jun;36 Suppl 48:135-8.
Intravenous immunoglobulin (IV Ig) has been shown its therapeutic value in primary immunodeficiency diseases associated with a profound impairement of IgG-mediated antibody production. In recent years its range of indications has been extended to some secondary immunodeficiency disorders such as chronic lymphocytic leukemia and children with symptomatic HIV infection IV Ig is also of value in cytomegalovirus infection in transplant recipients. The use of IV Ig in some immunoregulatory disorders, namely immune thrombocytopenic purpura and Kawasaki syndrome has also been proved. Preliminary studies suggests a benefit in myasthenia gravis, Guillain-Barré syndrome, polymyositis, chronic demyelinating diseases and steroid dependent asthma. Little is known about the mechanism of action of IV Ig in these immunoregulatory disorders. In sum, IV Ig has a few proved indications and many potential ones. Carefully controlled clinical trials are needed to determine the effectiveness of IV Ig in these conditions.
静脉注射免疫球蛋白（IV Ig）已在与IgG介导的抗体产生严重受损相关的原发性免疫缺陷疾病中显示出其治疗价值。近年来，其适应症范围已扩展到一些继发性免疫缺陷疾病，如慢性淋巴细胞白血病和有症状的HIV感染儿童。IV Ig在移植受者的巨细胞病毒感染中也有价值。IV Ig在一些免疫调节性疾病，即免疫性血小板减少性紫癜和川崎综合征中的应用也已得到证实。初步研究表明，其对重症肌无力、格林-巴利综合征、多发性肌炎、慢性脱髓鞘疾病和激素依赖性哮喘有益。关于IV Ig在这些免疫调节性疾病中的作用机制知之甚少。总之，IV Ig有一些已证实的适应症和许多潜在适应症。需要进行严格对照的临床试验来确定IV Ig在这些情况下的有效性。
